Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …
Despite recent improvements in treatment and prevention, most of the current therapeutic …
[HTML][HTML] Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2021 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …
Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial
E Martinelli, G Martini, V Famiglietti, T Troiani… - JAMA …, 2021 - jamanetwork.com
Importance Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs
has been suggested in patients with chemo-refractoryRASwild-type (WT) metastatic …
has been suggested in patients with chemo-refractoryRASwild-type (WT) metastatic …
Anti-EGFR rechallenge in patients with refractory ctDNA RAS/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial
Importance The available evidence regarding anti–epidermal growth factor receptor (EGFR)
inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) …
inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) …
[HTML][HTML] Unravelling the complexity of colorectal cancer: Heterogeneity, clonal evolution, and clinical implications
N Saoudi González, F Salvà, J Ros, I Baraibar… - Cancers, 2023 - mdpi.com
Simple Summary Metastatic colorectal cancer is a complex, prevalent, and life-threatening
disease influenced by various factors that affect its progression, evolution, and treatment …
disease influenced by various factors that affect its progression, evolution, and treatment …
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: A long and winding road
Emergence of acquired resistance limits the efficacy of the anti-EGFR therapies cetuximab
and panitumumab in metastatic colorectal cancer. In the last decade, preclinical and clinical …
and panitumumab in metastatic colorectal cancer. In the last decade, preclinical and clinical …
Cetuximab as a Key Partner in Personalized targeted therapy for metastatic colorectal Cancer
N Saoudi González, J Ros, I Baraibar, F Salvà… - Cancers, 2024 - mdpi.com
Simple Summary The treatment of colorectal cancer has been revolutionized in recent
decades by the identification of new targeted agents, particularly for metastatic colorectal …
decades by the identification of new targeted agents, particularly for metastatic colorectal …
Recent updates on the significance of KRAS mutations in colorectal cancer biology
The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this
review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming …
review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming …